Research and Markets Adds Report: Forest Laboratories - Product Pipeline Review - 2012

Print Share

Dec 21, 2012 (Close-Up Media via COMTEX) -- Research and Markets announced the addition of Global Markets Direct's new company profile "Forest Laboratories - Product Pipeline Review - 2012" to its offerings.

In a release, Research and Markets noted that report highlights include:

Global Market Direct's pharmaceuticals report, Forest Laboratories, Inc. - Product Pipeline Review - 2012 provides data on the Forest Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Forest Laboratories, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Forest Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Forest Laboratories, Inc. - Brief Forest Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.

- Review of current pipeline of Forest Laboratories, Inc. human therapeutic division.

- Overview of pipeline therapeutics across various therapy areas.

- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.

- Product profiles for late stage and clinical stage products of Forest Laboratories, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.

- Recent updates of the Forest Laboratories, Inc.'s pipeline in the last quarter.

- Key discontinued and dormant projects.

- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Forest Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline.

- Assess the growth potential of Forest Laboratories, Inc. in its therapy areas of focus.

- Identify new drug targets and therapeutic classes in the Forest Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

- Exploit collaboration and partnership opportunities with Forest Laboratories, Inc.

- Avoid Intellectual Property Rights related issues.

- Explore the dormant and discontinued projects of Forest Laboratories, Inc. and identify potential opportunities in those areas.

Report information:

http://www.researchandmarkets.com/research/jtth23/forest

((Comments on this story may be sent to newsdesk@closeupmedia.com))

Copyright Close-Up Media, Inc. 2012. All Rights reserved

**********************************************************************

As of Monday, 12-17-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated an UPTREND on
01-03-2012 for FRX @ $30.68.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.